Tamarack Advisers’s Haemonetics HAE Stock Holding History

Tamarack Advisers’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-500	Closed	-$24K	–	33
2019 Q4	$24K	Buy	+500	New	+$60.5K	0.01%	29

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Tamarack Advisers's HAE Position: Q3 2019 in Review

Tamarack Advisers sold out of Haemonetics (HAE) in Q3 2019, closing a stake of 100,000 shares — an estimated $12.1M sold.

Tamarack Advisers first reported a position in HAE in Q2 2019 and held it in 1 quarter. The position peaked at $12.1M in Q2 2019. 275 funds tracked by Wall St. Rank hold HAE as of Q3 2019.

Tamarack Advisers reported no remaining Haemonetics position as of Q3 2019 after selling out during the quarter.
Tamarack Advisers sold 100,000 Haemonetics shares in Q3 2019, an estimated $12.1M.
Tamarack Advisers first reported a position in Haemonetics in Q2 2019 and held it in 1 quarter.
Tamarack Advisers's Haemonetics position peaked at $12.1M in Q2 2019.
275 funds tracked by Wall St. Rank held Haemonetics as of Q3 2019.

Based on Tamarack Advisers's 13F filing for Q3 2019, filed 5 Nov 2019.